Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (32)	5/25/2006 1:53:51 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 210

Naturally the moleclues are very exciting and all that, those few pages of the s-4 make a good read. But I was also happy to see that Infinity has a license to Nexus (IRORI) RF tag technology. I had always wondered if there was something there, maybe so. Also, I have found at the top of page 89: "At March 31, 2006, Infinity had cash, cash equivalents and available-for-sale marketable securities of $23.9 million " I had posted over on my thread that I thought they had less than $5M, but that is not the case. So, they will close this deal sometime over the summer and ought to have three years of cash. Although, I would say if their molecules are good, they seem to have outlined many ways of burning a lot of cash very fast in clinical trials! So maybe the cash will be gone in two years, but a couple of aacr/asco cycles, and they can raise cash when they have to at higher valuations and I won't mind being diluted. Ha! I won't have my INFI for months and I am already imagining how I will tough out the inevitible cycles of dilution on the way to market. It'll be a long haul, but fun to watch.